Reskuin en es it fr


Reskuin Marchi, Reskuin Analoghi

Reskuin Marchi miscela

  • No information avaliable
  • Reskuin Formula chimica


    Reskuin RX link

    Reskuin FDA foglio

    Reskuin FDA

    Reskuin DMS (foglio di materiale di sicurezza)

    Reskuin Sintesi di riferimento

    Mitscher, Lester A. et al,. J.Med.Chem;. 30, 12, 2283-2286 (1987)

    Reskuin Peso molecolare

    740.751 g/mol

    Reskuin Temperatura di fusione

    No information avaliable

    Reskuin H2O Solubilita


    Reskuin Stato


    Reskuin LogP


    Reskuin Forme di dosaggio

    Compressa, liquidi; Soluzione

    Reskuin Indicazione

    Per il trattamento della congiuntivite batterica causata da ceppi sensibili dei seguenti organismi: specie Corynebacterium, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, , Streptococcus (Gruppi C / F / G), gli streptococchi del gruppo viridans, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.

    Reskuin Farmacologia

    Levofloxacina, un fluorochinolone antinfettivo, è otticamente attivo L-isomero di ofloxacina. Levofloxacina è usato per trattare la congiuntivite batterica, sinusite, bronchite cronica, polmonite acquisita in comunità e polmonite causata da ceppi resistenti alla penicillina di Streptococcus pneumoniae, infezioni della struttura della pelle e della pelle, infezioni complicate delle vie urinarie e pielonefrite acuta.

    Reskuin Assorbimento

    L'assorbimento di ofloxacina dopo dosi singole o multiple da 200 a 400 mg è prevedibile, e la quantità di farmaco assorbita aumenta proporzionalmente con la dose.

    Reskuin Tossicita

    Gli effetti collaterali includono disorientamento, vertigini, sonnolenza, vampate di calore e di freddo, nausea, impastando di parola, gonfiore e intorpidimento del viso

    Reskuin Informazioni paziente


    While taking ofloxacin patient should be advised to:

    to drink fluids liberally;

    that mineral supplements, vitamins with iron or minerals, calcium- , aluminum-, or magnesium-based antacids, sucralfate or Videx, (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution should not be taken within the two-hour period before or within the two-hour period after taking ofloxacin;

    that ofloxacin can be taken without regard to meals;

    that ofloxacin may cause neurologic adverse effects (e. g. , dizziness, lightheadedness) and that patients should know how they react to ofloxacin before they operate an automobile or machinery or engage in activities requiring mental alertness and coordination;

    to discontinue treatment and inform their physician if they experience pain, inflammation, or rupture of a tendon, and to rest and refrain from exercise until the diagnosis of tendinitis or tendon rupture has been confidently excluded;

    that ofloxacin may be associated with hypersensitivity reactions, even following the first dose, to discontinue the drug at the first sign of a skin rash, hives or other skin reactions, a rapid heartbeat, difficulty in swallowing or breathing, any swelling suggesting angioedema (e. g. , swelling of the lips, tongue, face; tightness of the throat, hoarseness), or any other symptom of an allergic reaction

    to avoid excessive sunlight or artificial ultraviolet light while receiving ofloxacin and to discontinue therapy if phototoxicity (e. g. , skin eruption) occurs;

    that if they are diabetic and are being treated with insulin or an oral hypoglycemic drug, to discontinue ofloxacin immediately if a hypoglycemic reaction occurs and consult a physician;

    that convulsions have been reported in patients taking quinolones, including ofloxacin, and to notify their physician before taking this drug if there is a history of this condition.

    Reskuin Atto interessato organismi

    Batteri enterici e altri eubatteri